Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 2020 ESC Guidelines for the management of adult congenital heart disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Predicting outcome in cardiac arrest: some progress, but more work needed

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: The study aimed to estimate the risk of cardiac events in immune checkpoint inhibitor (ICI)-treated patients with lung cancer or malignant melanoma.

METHODS AND RESULTS: The study included consecutive patients with lung cancer or malignant melanoma in 2011-17 nationwide in Denmark. The main composite outcome was cardiac events (arrhythmia, peri- or myocarditis, heart failure) or cardiovascular death. Absolute risks were estimated and the association of ICI and cardiac events was analysed in multivariable Cox models. We included 25 573 patients with lung cancer. Of these, 743 were treated with programmed cell death-1 inhibitor (PD1i) and their 1-year absolute risk of cardiac events was 9.7% [95% confidence interval (CI) 6.8-12.5]. Of the 13 568 patients with malignant melanoma, 145 had PD1i and 212 had cytotoxic T-lymphocyte-associated protein-4 inhibitor (CTLA-4i) treatment. Their 1-year risks were 6.6% (1.8-11.3) and 7.5% (3.7-11.3). The hazard rates of cardiac events were higher in patients with vs. without ICI treatment. Within 6 months from 1st ICI administration, the hazard ratios were 2.14 (95% CI 1.50-3.05) in patients with lung cancer and 4.30 (1.38-13.42) and 4.93 (2.45-9.94) in patients with malignant melanoma with PD1i and CTLA-4i, respectively. After 6 months, HRs were 2.26 (1.27-4.02) for patients with lung cancer and 3.48 (1.91-6.35) for patients with malignant melanoma and CTLA-4i.

CONCLUSIONS: Among patients with lung cancer and malignant melanoma, ICI treated had increased rates of cardiac events. The absolute risks were higher in these data compared with previous pharmacovigilance studies (e.g. 1.8% peri-/myocarditis 1-year risk).

Original languageEnglish
JournalEuropean Heart Journal
ISSN0195-668X
DOIs
Publication statusPublished - 9 Dec 2020

ID: 61434338